Andrew Berchuck

Overview:

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Positions:

James M. Ingram Distinguished Professor of Gynecologic Oncology

Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine

Professor of Obstetrics and Gynecology

Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine

Chief of Gynecologic Oncology

Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1980

Case Western Reserve University

Grants:

A Role of Multilevel Healthcare Access Dimensions in Ovarian Cancer Disparities

Administered By
Population Health Sciences
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

Endometrial Cancer TCGA Project

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Role
Principal Investigator
Start Date
End Date

Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Role
Principal Investigator
Start Date
End Date

TGCA Purchase Order

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Role
Principal Investigator
Start Date
End Date

Publications:

Publisher Correction: Shared heritability and functional enrichment across six solid cancers.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Authors
Jiang, X; Finucane, HK; Schumacher, FR; Schmit, SL; Tyrer, JP; Han, Y; Michailidou, K; Lesseur, C; Kuchenbaecker, KB; Dennis, J; Conti, DV; Casey, G; Gaudet, MM; Huyghe, JR; Albanes, D; Aldrich, MC; Andrew, AS; Andrulis, IL; Anton-Culver, H; Antoniou, AC; Antonenkova, NN; Arnold, SM; Aronson, KJ; Arun, BK; Bandera, EV; Barkardottir, RB; Barnes, DR; Batra, J; Beckmann, MW; Benitez, J; Benlloch, S; Berchuck, A; Berndt, SI; Bickeböller, H; Bien, SA; Blomqvist, C; Boccia, S; Bogdanova, NV; Bojesen, SE; Bolla, MK; Brauch, H; Brenner, H; Brenton, JD; Brook, MN; Brunet, J; Brunnström, H; Buchanan, DD; Burwinkel, B; Butzow, R; Cadoni, G; Caldés, T; Caligo, MA; Campbell, I; Campbell, PT; Cancel-Tassin, G; Cannon-Albright, L; Campa, D; Caporaso, N; Carvalho, AL; Chan, AT; Chang-Claude, J; Chanock, SJ; Chen, C; Christiani, DC; Claes, KBM; Claessens, F; Clements, J; Collée, JM; Correa, MC; Couch, FJ; Cox, A; Cunningham, JM; Cybulski, C; Czene, K; Daly, MB; deFazio, A; Devilee, P; Diez, O; Gago-Dominguez, M; Donovan, JL; Dörk, T; Duell, EJ; Dunning, AM; Dwek, M; Eccles, DM; Edlund, CK; Edwards, DRV; Ellberg, C; Evans, DG; Fasching, PA; Ferris, RL; Liloglou, T; Figueiredo, JC; Fletcher, O; Fortner, RT; Fostira, F; Franceschi, S; Friedman, E; Gallinger, SJ; Ganz, PA; Garber, J; García-Sáenz, JA; Gayther, SA; Giles, GG; Godwin, AK; Goldberg, MS; Goldgar, DE; Goode, EL; Goodman, MT; Goodman, G; Grankvist, K; Greene, MH; Gronberg, H; Gronwald, J; Guénel, P; Håkansson, N; Hall, P; Hamann, U; Hamdy, FC; Hamilton, RJ; Hampe, J; Haugen, A; Heitz, F; Herrero, R; Hillemanns, P; Hoffmeister, M; Høgdall, E; Hong, Y-C; Hopper, JL; Houlston, R; Hulick, PJ; Hunter, DJ; Huntsman, DG; Idos, G; Imyanitov, EN; Ingles, SA; Isaacs, C; Jakubowska, A; James, P; Jenkins, MA; Johansson, M; Johansson, M; John, EM; Joshi, AD; Kaneva, R; Karlan, BY; Kelemen, LE; Kühl, T; Khaw, K-T; Khusnutdinova, E; Kibel, AS; Kiemeney, LA; Kim, J; Kjaer, SK; Knight, JA; Kogevinas, M; Kote-Jarai, Z; Koutros, S; Kristensen, VN; Kupryjanczyk, J; Lacko, M; Lam, S; Lambrechts, D; Landi, MT; Lazarus, P; Le, ND; Lee, E; Lejbkowicz, F; Lenz, H-J; Leslie, G; Lessel, D; Lester, J; Levine, DA; Li, L; Li, CI; Lindblom, A; Lindor, NM; Liu, G; Loupakis, F; Lubiński, J; Maehle, L; Maier, C; Mannermaa, A; Marchand, LL; Margolin, S; May, T; McGuffog, L; Meindl, A; Middha, P; Miller, A; Milne, RL; MacInnis, RJ; Modugno, F; Montagna, M; Moreno, V; Moysich, KB; Mucci, L; Muir, K; Mulligan, AM; Nathanson, KL; Neal, DE; Ness, AR; Neuhausen, SL; Nevanlinna, H; Newcomb, PA; Newcomb, LF; Nielsen, FC; Nikitina-Zake, L; Nordestgaard, BG; Nussbaum, RL; Offit, K; Olah, E; Olama, AAA; Olopade, OI; Olshan, AF; Olsson, H; Osorio, A; Pandha, H; Park, JY; Pashayan, N; Parsons, MT; Pejovic, T; Penney, KL; Peters, WHM; Phelan, CM; Phipps, AI; Plaseska-Karanfilska, D; Pring, M; Prokofyeva, D; Radice, P; Stefansson, K; Ramus, SJ; Raskin, L; Rennert, G; Rennert, HS; van Rensburg, EJ; Riggan, MJ; Risch, HA; Risch, A; Roobol, MJ; Rosenstein, BS; Rossing, MA; De Ruyck, K; Saloustros, E; Sandler, DP; Sawyer, EJ; Schabath, MB; Schleutker, J; Schmidt, MK; Setiawan, VW; Shen, H; Siegel, EM; Sieh, W; Singer, CF; Slattery, ML; Sorensen, KD; Southey, MC; Spurdle, AB; Stanford, JL; Stevens, VL; Stintzing, S; Stone, J; Sundfeldt, K; Sutphen, R; Swerdlow, AJ; Tajara, EH; Tangen, CM; Tardon, A; Taylor, JA; Teare, MD; Teixeira, MR; Terry, MB; Terry, KL; Thibodeau, SN; Thomassen, M; Bjørge, L; Tischkowitz, M; Toland, AE; Torres, D; Townsend, PA; Travis, RC; Tung, N; Tworoger, SS; Ulrich, CM; Usmani, N; Vachon, CM; Van Nieuwenhuysen, E; Vega, A; Aguado-Barrera, ME; Wang, Q; Webb, PM; Weinberg, CR; Weinstein, S; Weissler, MC; Weitzel, JN; West, CML; White, E; Whittemore, AS; Wichmann, H-E; Wiklund, F; Winqvist, R; Wolk, A; Woll, P; Woods, M; Wu, AH; Wu, X; Yannoukakos, D; Zheng, W; Zienolddiny, S; Ziogas, A; Zorn, KK; Lane, JM; Saxena, R; Thomas, D; Hung, RJ; Diergaarde, B; McKay, J; Peters, U; Hsu, L; García-Closas, M; Eeles, RA; Chenevix-Trench, G; Brennan, PJ; Haiman, CA; Simard, J; Easton, DF; Gruber, SB; Pharoah, PDP; Price, AL; Pasaniuc, B; Amos, CI; Kraft, P; Lindström, S
MLA Citation
Jiang, Xia, et al. “Publisher Correction: Shared heritability and functional enrichment across six solid cancers..” Nat Commun, vol. 10, no. 1, Sept. 2019. Pubmed, doi:10.1038/s41467-019-12095-8.
URI
https://scholars.duke.edu/individual/pub1411881
PMID
31548585
Source
pubmed
Published In
Nature Communications
Volume
10
Published Date
Start Page
4386
DOI
10.1038/s41467-019-12095-8

Identification of novel epithelial ovarian cancer loci in women of African ancestry.

Women of African ancestry have lower incidence of epithelial ovarian cancer (EOC) yet worse survival compared to women of European ancestry. We conducted a genome-wide association study in African ancestry women with 755 EOC cases, including 537 high-grade serous ovarian carcinomas (HGSOC) and 1,235 controls. We identified four novel loci with suggestive evidence of association with EOC (p < 1 × 10-6 ), including rs4525119 (intronic to AKR1C3), rs7643459 (intronic to LOC101927394), rs4286604 (12 kb 3' of UGT2A2) and rs142091544 (5 kb 5' of WWC1). For HGSOC, we identified six loci with suggestive evidence of association including rs37792 (132 kb 5' of follistatin [FST]), rs57403204 (81 kb 3' of MAGEC1), rs79079890 (LOC105376360 intronic), rs66459581 (5 kb 5' of PRPSAP1), rs116046250 (GABRG3 intronic) and rs192876988 (32 kb 3' of GK2). Among the identified variants, two are near genes known to regulate hormones and diseases of the ovary (AKR1C3 and FST), and two are linked to cancer (AKR1C3 and MAGEC1). In follow-up studies of the 10 identified variants, the GK2 region SNP, rs192876988, showed an inverse association with EOC in European ancestry women (p = 0.002), increased risk of ER positive breast cancer in African ancestry women (p = 0.027) and decreased expression of GK2 in HGSOC tissue from African ancestry women (p = 0.004). A European ancestry-derived polygenic risk score showed positive associations with EOC and HGSOC in women of African ancestry suggesting shared genetic architecture. Our investigation presents evidence of variants for EOC shared among European and African ancestry women and identifies novel EOC risk loci in women of African ancestry.
Authors
Manichaikul, A; Peres, LC; Wang, X-Q; Barnard, ME; Chyn, D; Sheng, X; Du, Z; Tyrer, J; Dennis, J; Schwartz, AG; Cote, ML; Peters, E; Moorman, PG; Bondy, M; Barnholtz-Sloan, JS; Terry, P; Alberg, AJ; Bandera, EV; Funkhouser, E; Wu, AH; Pearce, CL; Pike, M; Setiawan, VW; Haiman, CA; African American Breast Cancer Consortium (AABC),; African Ancestry Prostate Cancer Consortium (AAPC),; Palmer, JR; LeMarchand, L; Wilkens, LR; Berchuck, A; Doherty, JA; Modugno, F; Ness, R; Moysich, K; Karlan, BY; Whittemore, AS; McGuire, V; Sieh, W; Lawrenson, K; Gayther, S; Sellers, TA; Pharoah, P; Schildkraut, JM; African American Cancer Epidemiology Study (AACES) and the Ovarian Cancer Association Consortium (OCAC),
MLA Citation
Manichaikul, Ani, et al. “Identification of novel epithelial ovarian cancer loci in women of African ancestry..” Int J Cancer, Aug. 2019. Pubmed, doi:10.1002/ijc.32653.
URI
https://scholars.duke.edu/individual/pub1406420
PMID
31469419
Source
pubmed
Published In
Int J Cancer
Published Date
DOI
10.1002/ijc.32653

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.
Authors
Armstrong, DK; Alvarez, RD; Bakkum-Gamez, JN; Barroilhet, L; Behbakht, K; Berchuck, A; Berek, JS; Chen, L-M; Cristea, M; DeRosa, M; ElNaggar, AC; Gershenson, DM; Gray, HJ; Hakam, A; Jain, A; Johnston, C; Leath, CA; Liu, J; Mahdi, H; Matei, D; McHale, M; McLean, K; O'Malley, DM; Penson, RT; Percac-Lima, S; Ratner, E; Remmenga, SW; Sabbatini, P; Werner, TL; Zsiros, E; Burns, JL; Engh, AM
MLA Citation
Armstrong, Deborah K., et al. “NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019..” J Natl Compr Canc Netw, vol. 17, no. 8, Aug. 2019, pp. 896–909. Pubmed, doi:10.6004/jnccn.2019.0039.
URI
https://scholars.duke.edu/individual/pub1412106
PMID
31390583
Source
pubmed
Published In
J Natl Compr Canc Netw
Volume
17
Published Date
Start Page
896
End Page
909
DOI
10.6004/jnccn.2019.0039

Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study.

BACKGROUND: Polycystic ovary syndrome (PCOS) is a complex endocrine disorder with an estimated prevalence of 4-21% in reproductive aged women. Recently, the Ovarian Cancer Association Consortium (OCAC) reported a decreased risk of invasive ovarian cancer among women with self-reported PCOS. However, given the limitations of self-reported PCOS, the validity of these observed associations remains uncertain. Therefore, we sought to use Mendelian randomization with genetic markers as a proxy for PCOS, to examine the association between PCOS and ovarian cancer. METHODS: Utilizing 14 single nucleotide polymorphisms (SNPs) previously associated with PCOS we assessed the association between genetically predicted PCOS and ovarian cancer risk, overall and by histotype, using summary statistics from a previously conducted genome-wide association study (GWAS) of ovarian cancer among European ancestry women within the OCAC (22 406 with invasive disease, 3103 with borderline disease and 40 941 controls). RESULTS: An inverse association was observed between genetically predicted PCOS and invasive ovarian cancer risk: odds ratio (OR)=0.92 [95% confidence interval (CI)=0.85-0.99; P = 0.03]. When results were examined by histotype, the strongest inverse association was observed between genetically predicted PCOS and endometrioid tumors (OR = 0.77; 95% CI = 0.65-0.92; P = 0.003). Adjustment for individual-level body mass index, oral contraceptive use and parity did not materially change the associations. CONCLUSION: Our study provides evidence for a relationship between PCOS and reduced ovarian cancer risk, overall and among specific histotypes of invasive ovarian cancer. These results lend support to our previous observational study results. Future studies are needed to understand mechanisms underlying this association.
Authors
Harris, HR; Cushing-Haugen, KL; Webb, PM; Nagle, CM; Jordan, SJ; Australian Ovarian Cancer Study Group,; Risch, HA; Rossing, MA; Doherty, JA; Goodman, MT; Modugno, F; Ness, RB; Moysich, KB; Kjær, SK; Høgdall, E; Jensen, A; Schildkraut, JM; Berchuck, A; Cramer, DW; Bandera, EV; Rodriguez, L; Wentzensen, N; Kotsopoulos, J; Narod, SA; McLaughlin, JR; Anton-Culver, H; Ziogas, A; Pearce, CL; Wu, AH; Lindström, S; Terry, KL
MLA Citation
Harris, Holly R., et al. “Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study..” Int J Epidemiol, vol. 48, no. 3, June 2019, pp. 822–30. Pubmed, doi:10.1093/ije/dyz113.
URI
https://scholars.duke.edu/individual/pub1393440
PMID
31211375
Source
pubmed
Published In
Int J Epidemiol
Volume
48
Published Date
Start Page
822
End Page
830
DOI
10.1093/ije/dyz113

Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer.

BACKGROUND: Randomized trials have reported conflicting findings on survival for advanced-stage ovarian cancer treated with primary debulking surgery (PDS) versus neoadjuvant chemotherapy with interval debulking; surgical complications and mortality are higher with PDS. We assessed women's preferences for tradeoffs related to this important clinical decision. METHODS: Ovarian cancer patients were recruited to complete a discrete-choice experiment (DCE) consisting of 8 choice tasks presenting experimentally designed treatment alternatives in terms of treatment order, extent of surgery including risk of ostomy, chance of death from surgical complications (1%-10%), readmission for surgical complications (5%-50%), progression-free survival (1-3 years), and overall survival (3-5 years). Random-parameters logit regression was applied to model participants' choices as a function of attribute levels. RESULTS: A total of 101 ovarian cancer survivors completed the DCE survey; of these participants, 30% were receiving chemotherapy at the time, and 33% had prior recurrence. Overall survival was of greatest importance to participants (36/100), followed by risk of readmission due to complications (23/100), progression-free survival (19/100), surgical mortality (16/100), extent of surgery (4/100), and order of surgery and chemotherapy (2/100). Overall, the participants would tolerate a 15-percentage point increase in risk of major complications (95% confidence interval [CI], 3%-29%) or a 4-percentage point increase in the risk of surgical mortality (95% CI, 2%-13%) in order to increase their expected overall survival from 3 to 3.5 years. CONCLUSIONS: Patients would accept a moderately higher risk of perioperative complications and surgical mortality in exchange for substantial gains in survival. These quantitative findings provide clinicians with a framework to discuss preferences with patients and to incorporate preferences into clinical trial design.
Authors
Havrilesky, LJ; Yang, J-C; Lee, PS; Secord, AA; Ehrisman, JA; Davidson, B; Berchuck, A; Darcy, KM; Maxwell, GL; Reed, SD
MLA Citation
Havrilesky, Laura J., et al. “Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer..” Cancer, vol. 125, no. 24, Dec. 2019, pp. 4399–406. Pubmed, doi:10.1002/cncr.32447.
URI
https://scholars.duke.edu/individual/pub1406386
PMID
31454432
Source
pubmed
Published In
Cancer
Volume
125
Published Date
Start Page
4399
End Page
4406
DOI
10.1002/cncr.32447

Research Areas:

3' Untranslated Regions
3-Oxo-5-alpha-Steroid 4-Dehydrogenase
5-Lipoxygenase-Activating Proteins
ABO Blood-Group System
ATP-Binding Cassette, Sub-Family B, Member 1
Acetaminophen
Actins
Actomyosin
Actuarial Analysis
Adaptor Proteins, Signal Transducing
Adenocarcinoma
Adenocarcinoma, Clear Cell
Adenocarcinoma, Mucinous
Adnexa Uteri
Adnexal Diseases
Adolescent
Adult
African Americans
African Continental Ancestry Group
Age Distribution
Age Factors
Age of Onset
Aged
Aged, 80 and over
Alcohol Dehydrogenase
Algorithms
Alkylating Agents
Alleles
Alternative Splicing
Americas
Amidohydrolases
Amino Acid Sequence
Aminopeptidases
Amnion
Analysis of Variance
Anemia
Aneuploidy
Angiogenic Proteins
Animals
Anthropometry
Anti-Inflammatory Agents, Non-Steroidal
Antibodies
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Antidepressive Agents
Antigens, CD
Antigens, CD31
Antigens, CD45
Antigens, CD80
Antigens, Tumor-Associated, Carbohydrate
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Combined Chemotherapy Protocols
Apolipoprotein A-I
Apoptosis
Apoptosis Regulatory Proteins
Arylamine N-Acetyltransferase
Ascites
Ascitic Fluid
Autophagy
Azacitidine
B7-1 Antigen
BRCA1 Protein
BRCA2 Protein
Base Sequence
Bayes Theorem
Binding Sites
Biopsy
Biopsy, Needle
Blood Coagulation
Blood Coagulation Disorders
Blood Coagulation Tests
Blood Loss, Surgical
Blood Transfusion
Blotting, Northern
Blotting, Southern
Blotting, Western
Body Height
Body Mass Index
Bone Marrow Transplantation
Brachytherapy
Brain Neoplasms
Breast
Breast Neoplasms
CA-125 Antigen
Cadherins
Caloric Restriction
Cancer
Carbon-Nitrogen Ligases
Carboplatin
Carcinoembryonic Antigen
Carcinoma
Carcinoma in Situ
Carcinoma, Adenoid Cystic
Carcinoma, Endometrioid
Carcinoma, Papillary
Carcinoma, Signet Ring Cell
Carcinoma, Small Cell
Carcinoma, Squamous Cell
Carcinosarcoma
Carrier Proteins
Case-Control Studies
Caspase 3
Caspase 8
Catalytic Domain
Cell Adhesion
Cell Culture Techniques
Cell Cycle
Cell Cycle Proteins
Cell Division
Cell Growth Processes
Cell Line
Cell Line, Transformed
Cell Line, Tumor
Cell Lineage
Cell Movement
Cell Proliferation
Cell Shape
Cell Survival
Cell Transformation, Neoplastic
Cells, Cultured
Cervix Uteri
Cesarean Section
Chemotherapy
Chemotherapy, Adjuvant
Chi-Square Distribution
Chickens
Child
Child, Preschool
Chloramphenicol O-Acetyltransferase
Choriocarcinoma
Chorionic Gonadotropin
Chromatin
Chromatography, Affinity
Chromatography, Liquid
Chromium
Chromium Compounds
Chromosome Aberrations
Chromosome Deletion
Chromosome Mapping
Chromosomes, Human, Pair 1
Chromosomes, Human, Pair 10
Chromosomes, Human, Pair 17
Chromosomes, Human, Pair 18
Chromosomes, Human, Pair 19
Chromosomes, Human, Pair 2
Chromosomes, Human, Pair 3
Chromosomes, Human, Pair 4
Chromosomes, Human, Pair 5
Chromosomes, Human, Pair 7
Chromosomes, Human, Pair 8
Chromosomes, Human, Pair 9
Cisplatin
Clinical Competence
Clinical Trials as Topic
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clone Cells
Cloning, Molecular
Cluster Analysis
Codon
Cohort Studies
Coitus
Colectomy
Collagen
Colon
Colon, Sigmoid
Colonic Neoplasms
Colorectal Neoplasms
Colorectal Neoplasms, Hereditary Nonpolyposis
Combined Modality Therapy
Comparative Effectiveness Research
Comparative Genomic Hybridization
Compliance
Condylomata Acuminata
Confidence Intervals
Confounding Factors (Epidemiology)
Contraception
Contraceptives, Oral
Contraceptives, Oral, Combined
Contraceptives, Oral, Hormonal
Cooperative Behavior
Cost-Benefit Analysis
Counseling
CpG Islands
Culture Media
Cyclin E
Cyclin-Dependent Kinase Inhibitor p16
Cyclin-Dependent Kinase Inhibitor p21
Cyclin-Dependent Kinases
Cyclins
Cyclophosphamide
Cystadenocarcinoma
Cystadenocarcinoma, Papillary
Cystadenocarcinoma, Serous
Cystadenoma, Mucinous
Cystadenoma, Serous
Cysts
Cytochrome P-450 CYP1A1
Cytochrome P-450 CYP3A
Cytokines
Cytostatic Agents
DNA
DNA (Cytosine-5-)-Methyltransferase
DNA (Cytosine-5-)-Methyltransferases
DNA Copy Number Variations
DNA Damage
DNA Fingerprinting
DNA Helicases
DNA Ligases
DNA Methylation
DNA Mismatch Repair
DNA Mutational Analysis
DNA Polymerase II
DNA Primers
DNA Repair
DNA, Complementary
DNA, Neoplasm
DNA, Satellite
DNA, Single-Stranded
DNA-Binding Proteins
Dactinomycin
Data Collection
Decision Support Techniques
Decision Trees
Deoxyribonucleases, Type II Site-Specific
Depression, Chemical
Dermatologic Surgical Procedures
Developed Countries
Diacylglycerol Kinase
Diagnosis, Differential
Diet
Dietary Supplements
Diffusion of Innovation
Dihydrouracil Dehydrogenase (NADP)
Dinoprostone
Diploidy
Discriminant Analysis
Disease Models, Animal
Disease Progression
Disease-Free Survival
Diseases
Dormancy
Dosage Compensation, Genetic
Dose-Response Relationship, Drug
Down-Regulation
Doxorubicin
Drug Administration Schedule
Drug Combinations
Drug Design
Drug Resistance
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Drug Synergism
E2F Transcription Factors
Early Detection of Cancer
Education, Medical, Graduate
Eflornithine
Eggs
Electrophoresis, Polyacrylamide Gel
Endometrial Hyperplasia
Endometrial Neoplasms
Endometriosis
Endometrium
Endosomal Sorting Complexes Required for Transport
Environmental Exposure
Enzyme Induction
Enzyme Inhibitors
Enzyme-Linked Immunosorbent Assay
Epidermal Growth Factor
Epigenesis, Genetic
Epigenomics
Epithelial Cells
Epithelium
Epitopes
Epoxide Hydrolases
Estradiol
Estrogen Antagonists
Estrogen Receptor alpha
Estrogen Receptor beta
Estrogen Replacement Therapy
Estrogens
Ethics, Medical
Ethnic Groups
Etoposide
Europe
European Continental Ancestry Group
Evaluation Studies as Topic
Exome
Exons
Extracellular Space
Factor IX
Fallopian Tube Neoplasms
Fallopian Tubes
Family planning
Fatigue
Fellowships and Scholarships
Female
Fetal Diseases
Fibrin Fibrinogen Degradation Products
Fibroblast Growth Factor 2
Fibroblast Growth Factors
Fibroblasts
Fibronectins
Fistula
Flow Cytometry
Fluorescent Antibody Technique
Fluorine Radioisotopes
Fluorodeoxyglucose F18
Folate Receptor 1
Folate Receptors, GPI-Anchored
Folic Acid
Follow-Up Studies
Forecasting
Formaldehyde
Frozen Sections
G1 Phase
GPI-Linked Proteins
GTP Phosphohydrolases
GTP-Binding Proteins
Galectin 1
Galectin 3
Gastrointestinal Diseases
Gene Amplification
Gene Deletion
Gene Dosage
Gene Expression
Gene Expression Profiling
Gene Expression Regulation
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
Gene Frequency
Gene Silencing
Gene Transfer Techniques
Gene-Environment Interaction
Genes, BRCA1
Genes, BRCA2
Genes, Neoplasm
Genes, Tumor Suppressor
Genes, cdc
Genes, fms
Genes, p16
Genes, p53
Genes, ras
Genetic Association Studies
Genetic Heterogeneity
Genetic Linkage
Genetic Loci
Genetic Markers
Genetic Predisposition to Disease
Genetic Testing
Genetic Therapy
Genetic Variation
Genetics
Genital Diseases, Female
Genital Neoplasms, Female
Genome, Human
Genome-Wide Association Study
Genomic Imprinting
Genomic Instability
Genomics
Genotype
Germ-Line Mutation
Glycoproteins
Gonadotropins
Granulocyte Colony-Stimulating Factor
Gravity Suits
Great Britain
Green Fluorescent Proteins
Growth Inhibitors
Growth Substances
Gynecologic Surgical Procedures
Gynecology
Half-Life
Haplotypes
HeLa Cells
Head and Neck Neoplasms
Health Care Costs
Health Planning Guidelines
Health Resources
Hemagglutinins
Hemorrhage
Heparin
Hepatocyte Nuclear Factor 1-beta
Heterocyclic Compounds with 4 or More Rings
Heterocyclic Compounds, 4 or More Rings
Heterozygote
Histones
Homeodomain Proteins
Homozygote
Hormone Replacement Therapy
Hormones
Humans
Hybrid Cells
Hydatidiform Mole
Hydrolysis
Hyperthermia, Induced
Hysterectomy
Image Processing, Computer-Assisted
Immunity
Immunoassay
Immunoblotting
Immunoenzyme Techniques
Immunohistochemistry
Immunologic Factors
Immunoradiometric Assay
Immunosuppressive Agents
Immunotherapy
Immunotoxins
In Situ Hybridization
Incidence
Infant
Infant, Newborn
Infection
Inflammation
Infusions, Parenteral
Injections, Intramuscular
Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor Binding Protein 2
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor Binding Proteins
Insulin-Like Growth Factor I
Insulin-Like Growth Factor II
Integrins
Intercellular Signaling Peptides and Proteins
Interferon-gamma
Interleukin-1
Interleukin-18
Interleukin-1alpha
Interleukin-6
International Agencies
International Cooperation
Internship and Residency
Interviews as Topic
Intracellular Signaling Peptides and Proteins
Intraoperative Complications
Introns
Kaplan-Meier Estimate
Keratins
Ki-67 Antigen
Kidney Diseases
Kinetics
Laminin
Laparoscopy
Laparotomy
Leiomyoma
Leiomyosarcoma
Length of Stay
Leucine Zippers
Leukocyte Common Antigens
Life Expectancy
Life Tables
Linear Models
Linkage Disequilibrium
Liver Diseases
Logistic Models
Longitudinal Studies
Loss of Heterozygosity
Lovastatin
Luciferases
Luminescent Proteins
Lung Diseases
Lung Neoplasms
Lymph Node Excision
Lymph Nodes
Lymphatic Diseases
Lymphatic Metastasis
Lymphedema
Lymphocyte Activation
Lymphocytes
Lymphocytes, Tumor-Infiltrating
Lysophospholipids
MAP Kinase Kinase 4
MAP Kinase Signaling System
Macaca fascicularis
Macrophage Colony-Stimulating Factor
Magnetics
Male
Mammary Neoplasms, Experimental
Marketing
Markov Chains
Matrix Metalloproteinase 1
Maximum Tolerated Dose
Medical History Taking
Medical Oncology
Medicine
Mefenamic Acid
Membrane Glycoproteins
Membrane Proteins
Membrane Transport Proteins
Menarche
Menopause
Menstrual Cycle
Menstruation Disturbances
Meta-Analysis as Topic
Metabolic Clearance Rate
Methods
Methotrexate
Methylation
Methylenetetrahydrofolate Dehydrogenase (NADP)
Mice
Mice, Inbred BALB C
Mice, Nude
MicroRNAs
Microarray Analysis
Microfilament Proteins
Micromanipulation
Microsatellite Instability
Microsatellite Repeats
Microscopy, Atomic Force
Microscopy, Confocal
Microscopy, Electron
Microspheres
Middle Aged
Mitochondrial Proteins
Mitosis
Mitotic Index
Mixed Tumor, Mesodermal
Mixed Tumor, Mullerian
Models, Biological
Models, Economic
Models, Genetic
Models, Statistical
Molecular Conformation
Molecular Sequence Data
Molecular Targeted Therapy
Molecular Weight
Morbidity
Mucin-1
Mullerian Ducts
Multicenter Studies as Topic
Multivariate Analysis
Muscle, Skeletal
MutS Homolog 2 Protein
Mutagenesis, Insertional
Mutation
Mycobacterium bovis
Myelin Proteins
Myelin and Lymphocyte-Associated Proteolipid Proteins
Myometrium
Myosin Type II
N-Acetylgalactosaminyltransferases
NAD(P)H Dehydrogenase (Quinone)
NF-kappa B
Neoplasm Grading
Neoplasm Invasiveness
Neoplasm Metastasis
Neoplasm Proteins
Neoplasm Recurrence, Local
Neoplasm Staging
Neoplasm Transplantation
Neoplasm, Residual
Neoplasms
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Multiple Primary
Neoplasms, Second Primary
Neoplastic Stem Cells
Neoplastic Syndromes, Hereditary
Neovascularization, Pathologic
Nerve Tissue Proteins
Neural Networks (Computer)
Neuropeptides
Neutropenia
Nicotinic Acids
North America
North Carolina
Nuclear Proteins
Nuclear Receptor Co-Repressor 1
Nuclear Receptor Co-Repressor 2
Nucleic Acid Heteroduplexes
Nucleic Acid Hybridization
Nutrition Disorders
Obesity
Observer Variation
Odds Ratio
Oligodeoxyribonucleotides
Oligonucleotide Array Sequence Analysis
Oligonucleotide Probes
Omentum
Oncogene Proteins, Viral
Oncogenes
Oncology Service, Hospital
Ornithine Decarboxylase
Ovarian Cysts
Ovarian Diseases
Ovarian Neoplasms
Ovariectomy
Ovary
Oviducts
Ovulation
Oxytocin
P-Glycoprotein
PTEN Phosphohydrolase
Paclitaxel
Pain, Postoperative
Palliative Care
Papillomaviridae
Paraffin Embedding
Parity
Patient Acceptance of Health Care
Patient Selection
Pedigree
Pelvic Exenteration
Pelvic Neoplasms
Pelvis
Peptide Elongation Factor Tu
Peptide Termination Factors
Peptides
Peripheral Nervous System Diseases
Peritoneal Cavity
Peritoneal Diseases
Peritoneal Lavage
Peritoneal Neoplasms
Peritoneum
Peritonitis, Tuberculous
Pharmacogenetics
Phenotype
Phosphates
Phosphatidate Phosphatase
Phosphatidylinositol 3-Kinases
Phosphoproteins
Phosphoric Monoester Hydrolases
Phosphorus Radioisotopes
Phosphorylation
Physical Examination
Pilot Projects
Piperidines
Placenta Accreta
Platelet Endothelial Cell Adhesion Molecule-1
Platelet-Derived Growth Factor
Platinum
Platinum Compounds
Ploidies
Pneumoperitoneum
Point Mutation
Poly(ADP-ribose) Polymerases
Polymerase Chain Reaction
Polymorphism, Genetic
Polymorphism, Restriction Fragment Length
Polymorphism, Single Nucleotide
Polymorphism, Single-Stranded Conformational
Population Dynamics
Population Surveillance
Postmenopause
Postoperative Complications
Postoperative Period
Powders
Practice Guidelines as Topic
Prealbumin
Precancerous Conditions
Precipitin Tests
Predictive Value of Tests
Pregnancy
Pregnancy Complications
Pregnancy Tests
Pregnancy Trimester, Second
Premenopause
Prenatal Diagnosis
Preoperative Care
Prevalence
Principal Component Analysis
Probability
Progesterone
Progestins
Prognosis
Proliferating Cell Nuclear Antigen
Promoter Regions, Genetic
Proportional Hazards Models
Prospective Studies
Prostaglandins
Prostaglandins E
Prostatic Neoplasms
Protamine Kinase
Protective Agents
Protein Array Analysis
Protein Isoforms
Protein Kinase C
Protein Kinase C-delta
Protein Kinase Inhibitors
Protein Precursors
Protein Processing, Post-Translational
Protein Structure, Tertiary
Protein Tyrosine Phosphatases
Protein-Serine-Threonine Kinases
Protein-Tyrosine Kinases
Proteins
Proteoglycans
Proteolipids
Proteomics
Proto-Oncogene Proteins
Proto-Oncogene Proteins B-raf
Proto-Oncogene Proteins c-bcl-2
Proto-Oncogene Proteins c-myb
Proto-Oncogene Proteins pp60(c-src)
Proto-Oncogenes
Purines
Pyrimidines
Quality Control
Quality of Life
Quality-Adjusted Life Years
Quantitative Trait Loci
Questionnaires
Quinone Reductases
RNA
RNA Splicing
RNA, Antisense
RNA, Messenger
RNA, Neoplasm
RNA, Small Interfering
RNA, Untranslated
ROC Curve
Radiation Injuries
Radioimmunoassay
Radioimmunoprecipitation Assay
Radiopharmaceuticals
Radiotherapy
Radiotherapy, Adjuvant
Randomized Controlled Trials as Topic
Rats
Rats, Sprague-Dawley
Real-Time Polymerase Chain Reaction
Receptor Protein-Tyrosine Kinases
Receptor, Epidermal Growth Factor
Receptor, IGF Type 2
Receptor, erbB-2
Receptors, Androgen
Receptors, Calcitriol
Receptors, Cell Surface
Receptors, Estrogen
Receptors, Growth Factor
Receptors, Interleukin-1
Receptors, Interleukin-2
Receptors, Laminin
Receptors, Progesterone
Receptors, Transforming Growth Factor beta
Receptors, Tumor Necrosis Factor
Reconstructive Surgical Procedures
Rectus Abdominis
Recurrence
Reference Values
Registries
Regression Analysis
Remission Induction
Reoperation
Repetitive Sequences, Amino Acid
Repetitive Sequences, Nucleic Acid
Repressor Proteins
Reproducibility of Results
Reproductive History
Retinoblastoma Protein
Retirement
Retrospective Studies
Reverse Transcriptase Polymerase Chain Reaction
Ricin
Risk
Risk Assessment
Risk Factors
Risk Reduction Behavior
Robotics
SEER Program
Sarcoma
Second-Look Surgery
Selective Estrogen Receptor Modulators
Sensitivity and Specificity
Sequence Analysis, DNA
Sequence Deletion
Serpins
Signal Transduction
Skin
Societies, Medical
Societies, Scientific
Socioeconomic Factors
Solubility
Specialization
Spheroids, Cellular
Staining and Labeling
Statistics, Nonparametric
Staurosporine
Sterilization, Tubal
Stimulation, Chemical
Stromal Cells
Sulfites
Surgical Flaps
Surgical Wound Dehiscence
Surgical Wound Infection
Surveys and Questionnaires
Survival
Survival Analysis
Survival Rate
Survivors
Sutures
T-Lymphocytes, Regulatory
TNF-Related Apoptosis-Inducing Ligand
Talc
Tamoxifen
Tandem Mass Spectrometry
Taxoids
Telomerase
Telomere
Terminal Care
Testis
Tetradecanoylphorbol Acetate
Tetrahydronaphthalenes
Therapies, Investigational
Thiazoles
Thigh
Thioguanine
Thiophenes
Thiotepa
Thrombocytosis
Thrombophlebitis
Thrombosis
Thrombospondin 1
Thymidine
Thymidylate Synthase
Time Factors
Tissue Array Analysis
Tissue Distribution
Tissue Embedding
Tissue Fixation
Tomography, Emission-Computed
Tomography, X-Ray Computed
Trans-Activators
Transcription Factors
Transcription, Genetic
Transcriptional Activation
Transfection
Transforming Growth Factor alpha
Transforming Growth Factor beta
Transforming Growth Factor beta1
Transforming Growth Factors
Transplantation, Autologous
Treatment Outcome
Tretinoin
Trinucleotide Repeats
Tritium
Trophoblastic Neoplasms
Tumor Cells, Cultured
Tumor Markers, Biological
Tumor Necrosis Factor-alpha
Tumor Suppressor Protein p53
Tumor Suppressor Proteins
United Kingdom
United States
Up-Regulation
Urologic Diseases
Utah
Uterine Cervical Diseases
Uterine Cervical Incompetence
Uterine Cervical Neoplasms
Uterine Hemorrhage
Uterine Neoplasms
Uterine Rupture
Uterus
Vagina
Vaginal Fistula
Vaginal Neoplasms
Vaginal Smears
Vanadates
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-1
Venous Thrombosis
Vincristine
Vulva
Vulvar Neoplasms
Wound Healing
X Chromosome
X-Linked Inhibitor of Apoptosis Protein
Xenobiotics
YY1 Transcription Factor
Young Adult
alpha-Fetoproteins
bcl-Associated Death Protein
ras Proteins
rho GTP-Binding Proteins
src-Family Kinases